Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed a method for treating and predicting treatment efficacy of triple negative breast cancer (TNBC).
Inventors at Stanford developed a method to leverage mass cytometry, a type of flow cytometry utilizing mass spectrometry, for the detection of heavy metals in leukocytes from individuals exposed to heavy metals in elevated air pollution.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Stanford scientists have discovered a novel method for treating neuroendocrine tumors by engineering T cells with Synthetic Notch (SynNotch) circuits that enable precise and durable tumor targeting while overcoming antigen heterogeneity.
Researchers in Dr. Bingwei Lu's lab have identified genes that could serve as therapeutic targets for the treatment of Parkinson's disease (PD). PD is a common neurodegenerative movement disorder affecting 1% of the population over the age 60.
Researchers at Stanford have developed methods to enhance bone healing in diabetic patients, who often suffer from impaired fracture healing due to a deficiency in hedgehog signaling in their skeletal stem cells.
Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have generated a crystal structure for human PD-1 in complex with one of its ligands, PD-L2, for use in small molecule inhibitor design.
Stanford researchers have developed an innovative microfluidic platform, EV-Lev, for the isolation and sorting of extracellular vesicles (EVs) from human plasma.
Researchers in Professor Justin Sonnenburg's laboratory have developed genetic tools for manipulating Bacteroides, a prominent genus of gut bacteria, for imaging, diagnostics, and therapeutic drug delivery.
Druggability of a protein is its potential to be modulated by drug-like molecules. It is important in the target selection phase. We developed DrugFEATURE to quantify druggability by assessing the microenvironments in potential small-molecule binding sites.
Stanford inventors have found that Stanniocalcin 2 (STC2) treatment following stoke leads to improved functional recovery and a pharmaceutical composition containing STC2 as an active ingredient can be used to facilitate post stroke recovery.
Stanford inventors in the Katrin Svensson laboratory have identified the protein Isthmin-1 (ISM1) as a treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Stanford researchers have discovered that Neat1, a long non-coding RNA, regulates degradation of the MYC protein, revealing a new target for treating MYC-dependent cancers.
Stanford scientists have developed a new DNA-based technology that allows therapeutic genes to be maintained in human cells for extended periods without altering the cell's chromosomes.